Skip to content

Cognitive and behavioral manifestations of the C9orf72 mutation in Amyotrophic Lateral Sclerosis: an age, education, and gender-matched cohort study.

Aug 2026 · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · pp. 1-8 · 0 citations · 34 references
Medicine

TL;DR

The findings suggest that the presence of the C9orf72 repeat expansion does not presage the development of significant cognitive or behavioral impairment early in the disease stage when controlled for age, years of education, and gender.

Abstract

Objectives

The presence of a hexanucleotide expansion in the gene C9orf72 confers a higher risk of developing ALS and FTD with associated cognitive and behavioral change, although penetrance is incomplete, and many gene carriers never exhibit any clinical signs during their lifetime. To date, there have been few studies investigating additional factors such as age, years of education, gender, and their influence on cognition and behavior in people with ALS (pwALS), particularly those with a hexanucleotide expansion in the gene C9orf72.

Methods

We selected 104 consenting pwALS from the Irish ALS register, comprising 52 C9orf72 positive participants and 52 C9orf72 negative controls matched on age, years of education, and gender. Cognitive functioning was assessed using the Edinburgh Cognitive and Behavioral ALS Screen (ECAS), while behavioral changes were examined using the Beaumont Behavioral Inventory (BBI).

Results

No significant differences in ECAS performance were observed across the two groups, with the exception of visuospatial performance, which was more impaired in those carrying the C9orf72 repeat expansion (p = .001). Similarly, there was no difference in behavoural scores between the 2 groups.

Conclusions

These findings suggest that the presence of the C9orf72 repeat expansion does not presage the development of significant cognitive or behavioral impairment early in the disease stage when controlled for age, years of education, and gender. When interpreting these results, it is important to consider the relatively small sample size, and the exclusion criteria of previous clinically significant comorbidities.

View source

Similar papers

Open access Aug 2026

The spectrum of C9orf72 repeat lengths in Portuguese frontotemporal dementia and amyotrophic lateral sclerosis patients: from pathogenic expansions to intermediate alleles

Introduction Frontotemporal dementia and amyotrophic lateral sclerosis are clinically distinct disorders that share a common genetic etiology, with pathogenic hexanucleotide repeat expansions in the C9orf72 gene representing the most frequent genetic cause of both conditions. In this study we aim to determine the frequ...

M. R. Almeida, M. Tábuas-Pereira, A. Matos et al. · 0 citations
Open access Sep 2026

Cognitive-behavioral phenotypes in FMR1 premutation carriers: a cross-population comparison with mild cognitive impairment

Introduction Carriers of the FMR1 premutation are at risk for cognitive decline, though premutation-specific markers of age-related risk are largely unknown. One approach to determining relevant risk markers is to assess cross-population comparisons with individuals with known clinical trajectories. Methods The present...

N. Maltman, Jessica L. Greenlee, K. Mueller et al. · 0 citations
Open access Sep 2026

Clinical Phenotype of Apoe Ɛ4 Carriers In Patients With Vascular Dementia: A Cross-Sectional Study From Indonesia

Background Vascular dementia (VaD) is the second most common cause of dementia and exhibits substantial heterogeneity in cognitive, functional, and radiological manifestations. Despite the observed differences in clinical presentation, the factors responsible for this variability have not been clearly identified. Whi...

Siti Giranti Ardilia Gunadi, Y. Fitrah, G. Soraya et al. · 0 citations
Open access Sep 2026

Plasma P-tau217, APOE Genotype, and the Timing of Cognitive Impairment in individuals Across Diverse Racial and Ethnic Groups: A Pooled Analysis of Prospective Cohort Studies

Findings support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention in appropriately selected at-risk individuals before the onset of clinical symptoms and support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention.

Yue-Xuan Xu, T. I. Gunasekaran, Yian Gu et al. · 1 citation
Open access Aug 2026

Theory of mind impairment related to C9orf72 repeat expansion in amyotrophic lateral sclerosis: a case-control study.

Objective: To investigate cognitive and affective theory of mind (ToM) in amyotrophic lateral sclerosis (ALS) patients carrying the C9orf72 repeat expansion (C9orf72+), compared with matched non-mutated (C9orf72-) ALS patients and healthy controls (HCs). Methods: We assessed 34 C9orf72+ ALS patients, 34 C9orf72- ALS pa...

F. Palumbo, B. Iazzolino, A. Canosa et al. · 0 citations
Open access Sep 2026

529. **Rafaelsen Award Presentation** Cognitive function and the risk of later onset of depression in healthy individuals: a 10-year longitudinal study

Abstract Background Cognitive impairments are common in individuals with depression, but their role in the etiology of the disorder remains unclear. Aims & Objectives In this 10-year longitudinal study, we tested whether cognitive function is associated with a risk for developing future first-episode depression in indi...

A. Sankar, B. Ozenne, V. Dam et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.